TFX Teleflex Incorporated

Teleflex Selects GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material for Use with Innovative Titan SGS® Stapler

Teleflex Selects GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material for Use with Innovative Titan SGS® Stapler

Product Pairing Offers an Impactful Partnership for Bariatric Surgery

WAYNE, Pa., March 29, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced a supply agreement with W. L. Gore & Associates, Inc. (Gore) to use Gore’s GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement material in a staple line reinforcement device designed by Teleflex for use with the Titan SGS® Powered Stapling Device. With these two innovative technologies paired together, bariatric surgeons will be able to utilize the advanced technology of the Titan SGS® Device with GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement material. Teleflex will provide specifics around future product commercialization dates.

“We recognize that GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement has nearly 20 years of market presence as a leading solution to help reduce bleeds and leaks in bariatric surgeries,” said James Ferguson, President, and General Manager, Surgical, Teleflex Incorporated. “As an emerging innovator in medical devices for bariatric surgery, we are excited to see the groundbreaking Titan SGS® Device continue to elevate the stapling technique by pairing two successful brands in a partnership that benefits the bariatric surgery space.”

Developed by Standard Bariatrics, Inc. now a part of Teleflex, the Titan SGS® Device is a sterile, single patient use instrument used for longitudinal transection and resection of the gastric tissue for sleeve gastrectomy pouch creation.1 It is the only stapler available in the United States with a specific FDA indication for sleeve pouch creation in bariatric procedures. The powered stapling Titan SGS® Device offers a range of benefits:

  • Shown to cut stapling time for a sleeve gastrectomy in half with one 55-second firing sequence.1,4
  • Helps surgeons deliver a more consistent and repeatable gastric sleeve anatomy with the industry’s longest continuous staple line of 23 cm with no overlapping staples.2,3

GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement is a synthetic buttressing material engineered to reduce leaks and bleeding and strengthen the staple line by redistributing the pressure exerted by an individual staple over a wider area5. More than 5 million devices* have been implanted globally, with more than 85 peer-reviewed clinical articles* supporting the use of GORE® SEAMGUARD® Reinforcement. In addition to the Titan SGS® Device, GORE® SEAMGUARD® Reinforcement material can be used with a variety of surgical staplers.

“We are proud that our product was sought out by Standard Bariatrics and Teleflex, to be integrated into their unique single fire stapler,” said Jake Goble, Business Leader, Gore’s Medical Products Division.

For bariatric surgeons who currently use a synthetic buttressing material to reduce perioperative leaks and bleeding with sleeve gastrectomy, the union of these medical products is welcome news.

Paul Enochs, MD, founding partner of Bariatric Specialists of North Carolina (now part of WakeMed Bariatric Surgery & Medical Weight Loss) Cary, NC, and Titan SGS® Device user said, “Staple line reinforcement is an important option that many surgeons depend on when performing bariatric operations to support hemostasis of staple lines. A leading innovator, GORE® SEAMGUARD® Reinforcement material offers years of dependable reliability and consistent performance. I am excited to hear it will be an option for surgeons using the Titan SGS® Platform for sleeve gastrectomy.”

Learn more about the Device and

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

About W. L. Gore & Associates, Inc.

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments—from outer space to the world’s highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.8 billion. For more information, visit .

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

GORE and SEAMGUARD are trademarks of W.L. Gore & Associates, Inc.

Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, Standard Bariatrics, Titan SGS, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2023 Teleflex Incorporated. All rights reserved. 

References:

1510(k) No. K210278. 28 Apr 2021. Retrieved from 

2Salyer, C. E., Thompson, J., Hoffman, A., Burstein, M. D., Enochs, P., Watkins, B. M., Kuethe, J., & Goodman, M. D. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surgical Endoscopy

3Salyer, C., Spuzzillo, A., Wakefield, D., Gomaa, D., Thompson, J., & Goodman, M. (2020 July). Assessment of a novel stapler performance for laparoscopic sleeve gastrectomy. Surgical Endoscopy, 35(7), 4016–4021.

4Varban, O. A., Niemann, A., Stricklen, A., Ross, R., Ghaferi, A. A., Finks, J. F., & Dimick, J. B. (2017, Aug.). Far from Standardized: Using Surgical Videos to Identify Variation in Technique for Laparoscopic Sleeve Gastrectomy. Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A, 27(8), 761–767.

5McCrea C. GORE® SEAMGUARD® Reinforcement family: Relationship between Design Inputs and “Engineered to reduce the incidence of perioperative leaks and bleeding”. Marketing statement. Flagstaff, AZ; 2015 [Work Plan] WP107241.

*Data on file 2023; W. L. Gore & Associates, Inc; Flagstaff, AZ

Paul Enochs is a paid consultant of Teleflex Incorporated and W.L. Gore & Associates, Inc.

Contacts:

Teleflex

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

610-948-2836



EN
29/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcar...

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at . About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the ...

 PRESS RELEASE

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a...

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for pur...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Teleflex Inc: 5 directors

Five Directors at Teleflex Inc bought 5,500 shares at between 114.750USD and 115.860USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch